2015
Borrelia miyamotoi infection in nature and in humans
Krause PJ, Fish D, Narasimhan S, Barbour AG. Borrelia miyamotoi infection in nature and in humans. Clinical Microbiology And Infection 2015, 21: 631-639. PMID: 25700888, PMCID: PMC4470780, DOI: 10.1016/j.cmi.2015.02.006.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsB. miyamotoi infectionMiyamotoi infectionClinical manifestationsB. miyamotoiLyme diseaseBorrelia miyamotoi infectionAcute febrile illnessCommon clinical manifestationsBlood smear examinationPublic health importanceHuman granulocytic anaplasmosisFever group spirochetesFebrile illnessAntibiotic therapyDisease groupEtiologic diagnosisSevere diseaseSmear examinationIxodes persulcatus ticksHealth importanceInfectionHuman casesGranulocytic anaplasmosisBorrelia miyamotoiDisease
2006
The Clinical Assessment, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: Clinical Practice Guidelines by the Infectious Diseases Society of America
Wormser GP, Dattwyler RJ, Shapiro ED, Halperin JJ, Steere AC, Klempner MS, Krause PJ, Bakken JS, Strle F, Stanek G, Bockenstedt L, Fish D, Dumler JS, Nadelman RB. The Clinical Assessment, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: Clinical Practice Guidelines by the Infectious Diseases Society of America. Clinical Infectious Diseases 2006, 43: 1089-1134. PMID: 17029130, DOI: 10.1086/508667.Peer-Reviewed Original ResearchConceptsInfectious Diseases SocietyHuman granulocytic anaplasmosisDiseases SocietyLyme diseasePost-Lyme disease syndromeGranulocytic anaplasmosisPrevious treatment guidelinesManagement of patientsClinical practice guidelinesEvidence-based guidelinesHealth care providersTickborne infectionTreatment guidelinesClinical manifestationsAntimicrobial therapyClinical assessmentPractice guidelinesCare providersDisease syndromeExpert panelDiseasePreventionPatientsTherapyInfection